NCT05989542View on ClinicalTrials.gov

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

PHASE3RecruitingINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

PLB1001

200mg BID Oral

Trial Locations (1)

510080

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
lead

Beijing Pearl Biotechnology Limited Liability Company

INDUSTRY